A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a promising pharmacological intervention in obesity management. This systematic review aimed to evaluate the efficacy and safety of semaglutide in promoting weight loss in adults…
BACKGROUND: To compare the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) versus bariatric surgery on cardiovascular outcomes in patients with heart failure (HF) with preserved ejection fraction and obesity. METHODS: Using the…
BACKGROUND: Off-label use of semaglutide as Ozempicfor weight loss has surged in the Arab populations in the absence of structured real-world evaluation. OBJECTIVE: To assess utilization patterns, effectiveness, and patient satisfaction with off-labe…
BACKGROUND: This meta-analysis aims to assess the association between exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and the incidence of suicidal behavior in patients with type 2 diabetes mellitus (T2DM)/obesity. METHODS: A compre…
INTRODUCTION AND OBJECTIVES: There is still limited evidence on the role of glucagon-like peptide-1 receptor agonists in heart failure. We analyzed the efficacy in terms of health status, and the change in body weight of once-weekly semaglutide in pa…
OBJECTIVE: This study aimed to characterize the reasons for treatment discontinuation with injectable semaglutide or tirzepatide for obesity in regular clinical practice. METHODS: This cross-sectional study used electronic health record data between…
BACKGROUND: Glucagon-like peptide-1 receptor agonist (GLP-1 RA) and glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist (GLP-1/GIP RA) use has become increasingly popular, leading to a rise in exposure calls to poiso…
AIMS: Trials of the Glucagon-like Peptide-1 Receptor Agonists (GLP1RAs) found mean weight losses of 15%-21%, yet realworld dose titration and persistence remain suboptimal, limiting effectiveness. This study aims to determine real-world titration, pe…
IntroductionDiabetes related foot ulcers (DFUs) are common complications of type 2 diabetes mellitus (T2DM), affecting 15-25% of individuals living with diabetes and significantly contributing to healthcare costs ($9-13 billion annually in the U.S.).…
Generic drugs have saved consumers billions of dollars in the United States. The demand for lower-cost and effective drugs, particularly for well-known peptide drugs like Ozempic and Wegovy (brand names for semaglutide), has resulted in a surge of ge…
INTRODUCTION: A stepwise coordinated multiple therapeutic targeted approach to the treatment of type 2 diabetes includes starting with lifestyle modification, oral antihyperglycemic agents, non-insulin injectables (Glucagon-like peptide-1 receptor ag…
Botulinum toxin, as a common facial wrinkle removal product, can be used for facial rejuvenation or improvement of skin texture, which is a commonly used cosmetic injectable product. However, botulinum toxin may lead to decreased immune function, cau…
GLP1 receptor agonists (GLP1-RAs) have become a central component in the treatment of type 2 diabetes mellitus (T2DM) and are gaining prominence in the cardiovascular field. Semaglutide and other GLP1-RA molecules possess cardioprotective properties.…
Heart failure with preserved ejection fraction (HFpEF) is a prevalent and complex condition with limited effective treatments. Endothelial dysfunction is a significant component of HFpEF pathophysiology, and glucagon-like peptide-1 receptor (GLP-1R)…
Semaglutide (SEMG) is one of the most widely used and trending medications to treat type II diabetes and obesity. This work aimed to develop a liquid chromatography with spectroflourimetric detection (HPLC-flourimetry) analysis of SEMG in both its ta…
PURPOSE: Semaglutide (Ozempic, Wegovy) has surged in popularity for its weight loss effects. Its widespread media coverage may have an outsized impact on adolescents and young adults due to their higher engagement in social media and their vulnerabil…
Recent evidence suggests that Glucagon-Like Peptide-1 receptor agonists (GLP-1RAs) can assist in alcohol and related substance use disorders (ASUD). GLP-1RAs act on the same receptor targets as native GLP-1, but last from several hours to a week, com…